Market Intelligence

Polpharma has struck a deal with MSN Laboratories that will see the Polish generics player distribute the Indian firm’s hospital portfolio in Poland.

Following the FDA’s approval of A 150mg version of Accord’ Herceptin biosimilar, the US agency has now greenlit a higher 400mg strength version of the rival.

During Hikma’s first-half results call, the company delved into details of its strategic goals for biosimilars, small-molecule generics, injectables, GLP-1s and more.

With a clear focus on complex products, Lupin sets out its launch plans for the year ahead, while battling ongoing litigation over some of its generics.

Sandoz has delivered the first denosumab biosimilar launch in Canada, introducing its Jubbonti and Wyost rivals to Amgen’s Prolia and Xgeva.

This article compiles all of the data from Generics Bulletin’s 2024 ranking of the Top 50 firms across the generics and biosimilars industry, including additional details of how the various financial figures stack up.

In the third instalment of this year’s Generics Bulletin Top 50, we look at some of the firms that have been eliminated from the bottom of our table as others have entered the picture.

In the second part of Generics Bulletin’s Top 50, we see some companies rising up the rankings of generics and biosimilars players worldwide, passing others that are moving in the opposite direction.

A deceptively familiar top 10 of generics and biosimilars industry leaders this year belies the significant evolutions seen for major off-patent players over the past 12 months. We reveal the changes under the surface in the first instalment of this year’s Generics Bulletin Top 50.

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Praesent venenatis quis felis semper hendrerit. Sed mattis libero ac dictum varius. Aliquam erat volutpat. Morbi scelerisque dolor neque, ut tristique tellus malesuada quis. Cras rhoncus velit sed nisi finibus pellentesque. Aliquam euismod, neque et dictum lacinia, elit ex consectetur.

This article compiles all of the data from Generics Bulletin’s 2023 ranking of the Top 50 firms across the generics and biosimilars industry, including additional details of how the various financial figures stack up.

In the third part of this year’s Generics Bulletin Top 50, we look at how various increases and declines for companies at the bottom of our table have affected their positions in the ranking.

In the second part of Generics Bulletin’s Top 50, we look at the mid-table players and how they have shifted positions this year.

In a year that has seen significant changes throughout our generics and biosimilars industry ranking, the top 10 has welcomed two Indian off-patent leaders after two other firms dropped out of the top table. We delve into what has changed in the first instalment of this year’s Generics Bulletin Top 50.

This article compiles all the data from Generics Bulletin’s 2022 ranking of the top 50 generics and biosimilars companies, including additional details of how the financial figures stack up.

In the third section of this year’s Generics Bulletin Top 50, a handful of new entrants make their way into the bottom of the rankings, while some volatility is seen among longstanding ranking companies.

Medium-sized generics and biosimilars players have seen ups and downs over the past year, with some changes to the order of these mid-table players seen as we continue to work our way through Generics Bulletin’s annual Top 50.

A new entrant into the top five global generics and biosimilars companies shows how transformations for some of the leading off-patent players are reshaping the industry landscape, with more major changes in the pipeline. We examine the 10 leaders of the pack in the first instalment of this year’s Generics Bulletin Top 50.

This article brings you a compilation of all the data from Generics Bulletin’s recent ranking of the top 50 generics and biosimilars companies, including additional details of how the financial figures stack up.